The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD). Clopidogrel showed a similar efficacy and safety than acetylsalicylic acid (ASA). More recently, the combined use of clopidogrel with ASA has evidenced a better protection than ASA alone in some patients: patients with past history of AMI, angina pectoris, intermittent claudication or PAD, IS or TIA, coronary bypass, and diabetes mellitus, patients on treatment with statins, and patients with symptomatic carotid stenosis ≥50%. We review the reported evidence on the efficacy of clopidogrel in the secondary prevention of ischemic stroke.
Keywords: IS (ischemic stroke), AMI (acute myocardial infarct), PAD (peripheral arterial disease), TIA (transient ischemic attack), ASA (acetylsalicylic acid), RRR (relative risk reduction), ARR (absolute risk reduction)
Rights & PermissionsPrintExport